Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.
暂无分享,去创建一个
Jeffrey J Delrow | J. Delrow | P. Greenberg | G. Hämmerling | N. Garbi | T. Schell | Varintra E Krisnawan | P. Lauer | D. Brockstedt | M. Philip | A. Schietinger | Andrea Schietinger | Peter Lauer | Philip D Greenberg | Mary Philip | Edison Y Chiu | Ryan S Basom | Dirk G Brockstedt | Sue E Knoblaugh | Günter J Hämmerling | Todd D Schell | Natalio Garbi | S. Knoblaugh | R. Basom | E. Chiu | Varintra E. Krisnawan
[1] M. Serrano,et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.
[2] Fabian Kiessling,et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction , 2008, Nature.
[3] Susan M. Kaech,et al. Transcriptional control of effector and memory CD8+ T cell differentiation , 2012, Nature Reviews Immunology.
[4] Michael R Stratton,et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma , 2014, Nature Medicine.
[5] A. Regev,et al. The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells , 2014, Nature Immunology.
[6] K. Hellström,et al. Cellular and Humoral immunity to Different Types of Human Neoplasms , 1968, Nature.
[7] D. Speiser,et al. Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion , 2015, The EMBO journal.
[8] Hans Schreiber,et al. Specificity in cancer immunotherapy. , 2008, Seminars in immunology.
[9] H. Schreiber,et al. Ribosomal versus non‐ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4+ T cells , 2010, Immunology.
[10] P. Kloetzel,et al. The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed. , 2011, Blood.
[11] J. Wolchok,et al. Cancer: Antitumour immunity gets a boost , 2014, Nature.
[12] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[13] Zoltan Szallasi,et al. In silico prediction of tumor antigens derived from functional missense mutations of the cancer gene census , 2012, Oncoimmunology.
[14] A. Wells,et al. Signals from CD28 Induce Stable Epigenetic Modification of the IL-2 Promoter1 , 2005, The Journal of Immunology.
[15] R. Hammer,et al. Comparative analysis of SV40 17kT and LT function in vivo demonstrates that LT's C-terminus re-programs hepatic gene expression and is necessary for tumorigenesis in the liver , 2012, Oncogenesis.
[16] Burton E. Barnett,et al. Progenitor and Terminal Subsets of CD8+ T Cells Cooperate to Contain Chronic Viral Infection , 2012, Science.
[17] D. Douek,et al. PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. , 2014, The Journal of clinical investigation.
[18] M. Giedlin,et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[19] M. Stratton,et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] I. Melero,et al. Orchestrating immune check-point blockade for cancer immunotherapy in combinations. , 2014, Current opinion in immunology.
[21] Pedro Romero,et al. Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. , 2011, The Journal of clinical investigation.
[22] M. Pfreundschuh,et al. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[24] Björn Nilsson,et al. Integrative genomic analysis of HIV-specific CD8+ T cells reveals that PD-1 inhibits T cell function by upregulating BATF , 2010, Nature Medicine.
[25] R. Ahmed,et al. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. , 2011, Immunity.
[26] E. Wherry,et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. , 2007, Immunity.
[27] S. Kaech,et al. Generation of effector CD8+ T cells and their conversion to memory T cells , 2010, Immunological reviews.
[28] A. Secord,et al. Priming and Activation of Human Ovarian and Breast Cancer-specific CD8+ T Cells by Polyvalent Listeria monocytogenes-based Vaccines , 2009, Journal of immunotherapy.
[29] D. Douek,et al. Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression , 2013, The Journal of Immunology.
[30] A. Mackensen,et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. , 2004, Cancer research.
[31] M. J. Tevethia,et al. In Vivo Ligation of CD40 Enhances Priming Against the Endogenous Tumor Antigen and Promotes CD8+ T Cell Effector Function in SV40 T Antigen Transgenic Mice1 , 2003, The Journal of Immunology.
[32] T. Welling,et al. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. , 2013, Current opinion in immunology.
[33] Jimmy Lin,et al. Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.
[34] Maxim N. Artyomov,et al. Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens , 2014, Nature.
[35] E. Appella,et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes , 1996, The Journal of experimental medicine.
[36] S. Kaufmann,et al. Role of CD28 for the Generation and Expansion of Antigen-Specific CD8+ T Lymphocytes During Infection with Listeria monocytogenes1 , 2001, The Journal of Immunology.
[37] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[38] C. Huber,et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[39] P. Greenberg,et al. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. , 2014, Trends in immunology.
[40] D. Gabrilovich,et al. Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.
[41] D. Fearon,et al. T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.
[42] Antonio Polley,et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection , 2009, Nature Immunology.
[43] J. Wolchok,et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. , 2015, The New England journal of medicine.
[44] J. Delrow,et al. Rescued Tolerant CD8 T Cells Are Preprogrammed to Reestablish the Tolerant State , 2012, Science.
[45] Sven Malchow,et al. Basic principles of tumor-associated regulatory T cell biology. , 2013, Trends in immunology.
[46] G. Hämmerling,et al. Tumor agonist peptides break tolerance and elicit effective CTL responses in an inducible mouse model of hepatocellular carcinoma. , 2009, Immunology letters.
[47] E. Wherry,et al. A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. , 2009, Immunity.
[48] G. Freeman,et al. Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.
[49] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[50] S. Rosenberg,et al. Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.
[51] K. Isobe,et al. Cutting Edge: CD8+CD122+ Regulatory T Cells Produce IL-10 to Suppress IFN-γ Production and Proliferation of CD8+ T Cells1 , 2005, The Journal of Immunology.
[52] R. Maronpot,et al. Histologic Characterization of Hepatic Carcinogenesis in Transgenic Mice Expressing SV40 T-antigens , 1993, Veterinary pathology.
[53] G. Willimsky,et al. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance , 2005, Nature.
[54] Kristin A. Hogquist,et al. T cell receptor antagonist peptides induce positive selection , 1994, Cell.
[55] Jeffrey W Pollard,et al. Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.